Skip to main content

Table 3 Comparison of the baseline characteristics of responders within the first three months of erenumab treatment versus non-responders

From: Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

CharacteristicResponders (n = 64)Non-respondersa (n = 25)P value
Female, n (%)54 (84.4)24 (96.0)0.134
Age, median (IQR)48 (38–52.5)52.5 (42–56)0.358
Years of migraine history, median (IQR)28 (19.5–34.5)25 (18–32)0.467
MMDs, median (IQR)18 (12–27.5)26.5 (20–30)0.026
Analgesic days, median (IQR)8 (2.5–22)20 (11–29)0.008
Triptan days, median (IQR)3 (0–16.5)1 (0–20)0.532
Chronic migraine, n (%)59 (92.2)25 (100.0)0.150
Aura, n (%)18 (28.1)9 (36.0)0.468
Allodynia, n (%)23 (35.9)10 (40.0)0.721
Medication overuse, n (%)45 (70.3)19 (76.0)0.592
Prior preventive treatment failures, n (%)  0.560
 218 (28.1)10 (40.0) 
 > 246 (71.9)15 (60.0) 
Botulinum toxin failure, n (%)31 (48.4)13 (52.0)0.763
  1. aincluding 12 patients with < 50% reduction of MMDs from baseline and 13 patients who discontinued treatment
\